Given the amount of funding you've raised and the length of time you have been around, what can you offer in the way of confidence of the 36 month strategy to an IPO or partnership (and why those two as a target in 3 years time?). Sorry to sound skeptical but it's a very diffe...

Hi Ethan, of note, we have begun outreach to large pharmaceutical companies seeking partnerships or licensing of our technology, and we have already met with interest from a couple of overseas large Pharma. They would like to see some data comparing mRNA to our viral vector, as the former is such a hot thing right now! (as it is a potent biological tool for vaccines, which I'm sure you know from COVID). We've obtained funding to execute that very experiment, and are already underway! We're co...

Hey Arthur, this is a super cool company. Love what you’re focused on. Congratulations on the recent Duke grant win. Way to go! Would you please consider answering a few questions that I have? I noticed that the intention for some of the money resulting from this capital raise...

Hi Justin, Thanks for these great questions! We've been branching out to other pathogens beside flu virus for a few reasons. First, we've completed all the preclinical proof-of-concept studies for our flu vaccine with the exception of two experiments, which we are going to do with our Duke grant. Since we're outsourcing these mouse studies, and since beyond that point, it's a lot of "waiting" around while our product goes through the long regulatory process, there's a lot of time and opportun...

Hello, As a critical care respiratory therapist, now physician assistant, I have dealt with so many of these respiratory viruses; h1n1, covid, other flu strains dealing with the sickest of patients. This research/tech could be ground breaking if you are able to succeed. You me...

Hi Adam, Sorry for the delayed response. We do have two patents that have been granted for our flu vaccine, which is protecting the eleven sequence stretches in flu which are invariant (cannot be mutated without lethal consequence to virus). These sequence stretches make up the composition of our vaccine, such that it is not susceptible to viral mutational escape like all other flu vaccines are. There are a few possible answers to your question about why we believe we will succeed. First, we ...

Does your patent apply to the technology in general, or just to your flu vaccine?

Hi Michael, Thanks for asking. Our two patents are on the flu vaccine composition. It's very difficult to patent a method these days. However, we've got flu covered because we know no one else is going to find superior (or equal) targets, since we surveyed the whole genome and took the 11 best targets. As for the technological platform, we're underway in applying it to other viruses to meet unmet medical needs. The platform is quite labor-intensive and tricky, which makes it difficult for oth...

Hey Arthur, me again. It was really exciting to see the company's recent update, great work! And thank you for the detailed answer below. Would you mind commenting on how many months of runway InnVax has given it's approximate burn rate going forward? It's unclear to me exactl...

Hey Justin, We're being powered mostly by federal grants right now, so our runway is based on that. We're burning approx. $60k a month, and are guaranteed at least 2.5 more years from grants. But, it's a relatively fluid situation; for example, we expect to receive a new 2 year grant pretty soon.

InvVax Updates, Team, and Funding Progress | Wefunder, Home of the Community Round

Huge global market for these vaccines: Universal flu - $22B; COVID-19 - $5B

Chance to make an enormous societal impact

Patented durable and universal flu vaccine

Major smashes: Moderna, BioNTech, Novavax: Invest in the next one!

Backed by Life Science Angels - #1 US angel group (CB Insights), Sand Hill Angels, Tech Coast Angels

Funded by the DoD and the NSF

InvVax

We use a new genetics platform to develop better vaccines for flu, COVID-19, etc

$124,203

InvVax

Quick facts

Team profiles

Featured investor profiles

$124,203

Ask